NBE Therapeutics is a cutting-edge biotech company based in Basel, Switzerland. Founded in 2012, NBE Therapeutics has quickly established itself as a leader in the field of antibody drug conjugates (ADCs) for targeted cancer therapy. In December 2020, the company was acquired by Boehringer Ingelheim, a renowned German pharmaceutical company, making NBE Therapeutics a wholly owned subsidiary.

NBE Therapeutics specializes in the development of innovative technologies, including Transpo-mAb™ and SMAC-Technology™, which enable the precise delivery of potent anti-cancer payloads to tumor cells while sparing healthy tissue. One such payload is the PNU anthracycline, known for its impressive efficacy. With a robust pipeline of ADC candidates, NBE Therapeutics is at the forefront of advancing the field of immune oncology.

Their groundbreaking research and development efforts have been recognized through numerous publications and industry events. If you're looking to join a dynamic and pioneering team dedicated to transforming cancer treatment, NBE Therapeutics offers exciting career opportunities. Contact them today and be part of the future of oncology